Syndax Pharmaceuticals (SNDX) Other Non Operating Income (2015 - 2026)
Syndax Pharmaceuticals' (SNDX) quarterly Other Non Operating Income came in at -$186000.0 in Q1 2026, up 15.84% year-on-year from -$160570.3 in Q1 2025, and up 68.26% quarter-over-quarter from -$586000.0 in Q4 2025.
Syndax Pharmaceuticals (SNDX) Other Non Operating Income (2015 - 2026) Analysis & Trends
Syndax Pharmaceuticals' Other Non Operating Income history runs 12 years deep, the most recent figure standing at -$186000.0 for Q1 2026.
- On a quarterly basis, Other Non Operating Income rose 15.84% year-over-year to -$186000.0 in Q1 2026; TTM through Mar 2026 was -$1.3 million, a 232.81% decrease from a year earlier, with the FY2025 full-year figure at -$1.3 million, down 419.43% from the prior year.
- Other Non Operating Income grew to -$186000.0 in Q1 2026 per SNDX's latest filing, from -$586000.0 in the prior quarter.
- Across five years, Other Non Operating Income topped out at $116000.0 in Q1 2022 and bottomed at -$586000.0 in Q4 2025.
- The 5-year median for Other Non Operating Income is -$99500.0 (2022), against an average of -$137000.0.
- Across the five-year window, Other Non Operating Income surged 303.51% in 2022 and slumped 959.38% in 2025, its largest moves.
- Year by year, Other Non Operating Income stood at -$106000.0 in 2022, then soared by 48.11% to -$55000.0 in 2023, then tumbled by 92.73% to -$106000.0 in 2024, then slumped by 452.83% to -$586000.0 in 2025, then jumped by 68.26% to -$186000.0 in 2026.
- Per Business Quant, the three latest SNDX Other Non Operating Income figures stand at -$186000.0 (Q1 2026), -$586000.0 (Q4 2025), and -$275000.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Syndax Pharmaceuticals | 1.87 Bn | 1.52 Bn | 53.02 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -186,000.00 |
| Dec 31, 2025 | -586,000.00 |
| Sep 30, 2025 | -275,000.00 |
| Mar 31, 2025 | -221,000.00 |
| Dec 31, 2024 | -106,000.00 |
| Sep 30, 2024 | 32,000.00 |
| Jun 30, 2024 | -86,000.00 |
| Mar 31, 2024 | -87,000.00 |
| Dec 31, 2023 | -55,000.00 |
| Sep 30, 2023 | -66,000.00 |
| Jun 30, 2023 | -93,000.00 |
| Mar 31, 2023 | -147,000.00 |
| Dec 31, 2022 | -106,000.00 |
| Sep 30, 2022 | -295,000.00 |
| Jun 30, 2022 | -31,000.00 |
| Mar 31, 2022 | 116,000.00 |
| Dec 31, 2021 | 351,000.00 |
| Sep 30, 2021 | -41,000.00 |
| Jun 30, 2021 | -50,000.00 |
| Mar 31, 2021 | -57,000.00 |